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ABSTRACT
Leptospirosis has a highly variable clinical presentation, which may be related to different infecting
serovars, host factors, or a combination of these. This study investigated retrospectively 34 consecutive
patients with serologically conﬁrmed leptospirosis admitted during the period 1992–2002. On
admission, the most frequent symptoms were fever (100%), headache (75%), myalgia (55%), arthralgia
(45%) and vomiting (39%). Pertinent laboratory ﬁndings included lymphopenia (85%), thrombocy-
topenia (75%), elevated liver enzymes (87%) and renal abnormalities (proteinuria, 77%; haematuria,
58%; elevated serum creatinine, 53%). The study conﬁrmed the variable clinical and biological
symptoms of leptospirosis, and indicated that lymphopenia is a common feature of leptospirosis cases.
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INTRODUCTION
Leptospirosis is a worldwide zoonotic disease
caused by spirochaetes of the genus Leptospira
[1,2]. Human infections are endemic in most
tropical and temperate climates. Leptospirosis
has a highly variable clinical presentation, which
may be related to different infecting serovars, host
factors, or a combination of these [1–3]. Between
500 and 1000 cases occur each year in territories
administered by France, mostly in tropical
climates (West Indies, Polynesia, La Re´union,
French Guyana, New Caledonia). However, met-
ropolitan France has one of the lowest reported
incidences of leptospirosis in western Europe
(0.44 cases ⁄ 100 000 population in 1998) [4].
Pontchaillou Hospital is a tertiary-care univer-
sity-afﬁliated hospital which serves as a referral
centre for Ille et Vilaine, a rural area of 900 000
inhabitants, with an estimated annual incidence
of leptospirosis of 0.62 ⁄ 100 000 population [5].
The present report describes a retrospective study
of 34 consecutive patients with serologically
conﬁrmed leptospirosis admitted to Pontchaillou
Hospital between 1992 and 2002.
PATIENTS AND METHODS
Case reports of leptospirosis between 1992 and 2002 were
investigated. Cases were identiﬁed using the Leptospirosis
Registry at the Department of Bacteriology, Hoˆpital Sud,
Rennes. For a case to qualify as a conﬁrmed case of
leptospirosis, all three of the following criteria were
required: (1) a clinically compatible illness; (2) the presence
of thermo-resistant antigen [6] or an IgM antibody titre
(ELISA) of at least 1:400 [7]; and (3) a positive microscopic
agglutination test result, with a titre of at least 1:100 [8].
These criteria are considered to be indicative of recent or
current leptospirosis in areas with a low incidence [2].
Isolation of leptospires is not performed routinely at
Pontchaillou University Hospital. As deﬁnitive identiﬁcation
is not possible with the microscopic agglutination test because
of cross-agglutination or cross-reactivity between serovars or
different serogroups, infecting serovars were identiﬁed pre-
sumptively on the basis of the serovar showing the highest
titre at 1 month after the appearance of symptoms, but only for
cases that demonstrated a four-fold increase in microscopic
agglutination test titre between acute- and convalescent-phase
sera [1–3]. If there was more than one serovar with the same
Corresponding author and reprint requests: P. Tattevin,
Infectious Diseases and Intensive Care Unit, Pontchaillou
University Hospital, 35033 Rennes Cedex, France
E-mail: pierre.tattevin@chu-rennes.fr
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
high titre, the presumptive infecting serovar was designated as
‘indeterminate’ [3]. All serological tests were performed by the
National Leptospirosis Reference Centre, Institut Pasteur,
Paris, France.
A standardised case investigation form was used to
compile demographical, epidemiological, clinical and labor-
atory data. To assess the possible source of exposure,
patients were asked about high-risk activities that had
occurred during the 30-day period before the onset of
symptoms. These included exposure to rats or potentially
contaminated fresh water through occupational activities
(e.g., farming), recreational activities (e.g., canoeing, fresh-
water swimming, ﬁshing, hiking) or home-based activities
(e.g., gardening, trapping rats).
RESULTS
Cases of leptospirosis
In total, 34 cases of leptospirosis were conﬁrmed
serologically between 1992 and 2002, with males
accounting for 28 (82%) cases. The median age
of the infected patients was 43 years (SD
5.8 years; range 12–70 years). During the
30 days before the onset of symptoms, 24
(70%) patients reported high-risk activities,
mostly recreational, including canoeing (n = 9),
hunting or ﬁshing (n = 6), farming or aquacul-
ture (n = 5) and freshwater swimming (n = 4).
Two patients probably acquired leptospirosis
during travel outside France (Ivory Coast and
China, one patient each).
Upon admission, the average body temperature
of infected patients was 40C (SD 0.3C). The most
common symptoms were headache (75%), myal-
gia (55%), arthralgia (45%) and vomiting (39%)
(Table 1). Pertinent initial laboratory results inclu-
ded lymphopenia (85%), thrombocytopenia
(75%) and evidence of hepatic abnormalities
(87%) or renal abnormalities (proteinuria 77%,
haematuria 58%, elevated serum creatinine 53%).
All patients were hospitalised, with a median
duration of 4 days after the ﬁrst symptoms, in the
infectious diseases unit (n = 17), the intensive care
unit (ICU) (n = 5), the nephrology department
(n = 4), the internal medicine department (n = 4),
the hepatology department (n = 3) or the paedi-
atrics department (n = 1).
Results of serological testing
Initial serological testing for leptospirosis anti-
bodies (ELISA) was positive for only 16 (47%)
cases. Eventual presumptive infecting serovars
for the 34 patients were Grippotyphosa (n = 10),
Icterohaemorrhagiae (n = 5), Copenhageni
(n = 4), Australis (n = 3), Cynopteri (n = 1) and
indeterminate (n = 11).
ICU patients
Five (15%) patients were admitted to the ICU
following acute renal failure that required dialysis
(n = 2), diffuse alveolar haemorrhage and pul-
monary artery hypertension (n = 1), congestive
heart failure (n = 1) or encephalitis (n = 1). The
median stay in the ICU was 6 days (range 3–
10 days). Among these ﬁve patients, two were
infected presumptively with Leptospira serovar
Copenhageni. Thus, of the four patients infected
presumptively with this serovar, 50% were
admitted to the ICU, compared with three (10%)
of the 30 patients infected presumptively with
other serovars or an indeterminate serovar (not
signiﬁcant).















Abdominal pain 34.3 32
Jaundice 34.3 32







Haemoglobin < 12 g ⁄dL 25.0 32
WBC >10 800 ⁄mm3 18.7 32
WBC <4800 ⁄mm3 18.7 32
Lymphocytes < 1000 ⁄mm3 85.1 27
Platelet count < 150 000 ⁄mm3 75.0 32
Fibrinogen > 4 g ⁄L 95.0 20
Creatinine > 120 lmol ⁄L 53.3 30
ALAT >40 IU ⁄L 86.6 30
ASAT >40 IU ⁄L 83.3 30
Bilirubinaemia > 20 lmol ⁄L 52.0 25
Rhabdomyolysis > 195 IU ⁄L 47.1 17
Cerebrospinal ﬂuid
WBC >5 ⁄mm3 55.5 18
Neutrophils > 70% 22.2 9
Lymphocytes > 70% 11.1 9
Mixed cellularity 66.6 9
Proteinorachy > 1 g ⁄L 22.2 9
aMaculopapular lesions (n = 7), pharyngeal injection (n = 4), purpura (n = 1).
bCough (n = 4), cyanosis (n = 2), dyspnoea (n = 1), haemoptysis (n = 1), crackles
(n = 1).
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; WBC, white
blood cells.
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Treatment and outcome
Twenty-ﬁve (80%) patients received antibiotics,
including 20 (60%) patients who received a
b-lactam agent as ﬁrst-line treatment. Three
(15%) of these 20 patients had symptoms sug-
gestive of a Jarish Herxeimer reaction following
the ﬁrst administration of the b-lactam agent.
Other antibiotics prescribed included ﬂuoroqui-
nolones (n = 2), cyclines (n = 1), co-trimoxazole
(n = 1) and macrolides (n = 1). Seven (22%)
patients did not receive antibiotics. Data regard-
ing antibiotic treatment were not available for two
patients. All 34 patients made a full recovery.
DISCUSSION
Few studies have used consistent laboratory
criteria that allow valid comparisons between
the clinical and epidemiological patterns of lepto-
spirosis in different populations. Most case series
published to date have included patients without
laboratory conﬁrmation [9], or with less speciﬁc
case deﬁnitions for the purpose of conﬁrmation
[10–17]. Such studies have been performed in the
USA [3,9], Brazil [16], The Seychelles [13], New
Caledonia [11], India [15], Israel [14] and Den-
mark [17]. The present series comprised most
patients admitted for leptospirosis within the
catchment area of Pontchaillou Hospital between
1992 and 2002.
The symptoms reported in the present study
were consistent with those reported in other
series, with fever, headache, myalgia, arthralgia
and vomiting being the most common presenta-
tions [1,9,10,14,15,18]. Rash was more frequent in
this series (37.5%) than is usually reported. This
could suggest that the clinical presentation of
leptospirosis is somewhat different in the Pontc-
haillou area of France, but may also be related to
differences in physicians’ evaluations. The labor-
atory ﬁndings in the study were also similar to
descriptions published elsewhere, with thrombo-
cytopenia and elevated liver enzymes being com-
mon [1,3,11,13,19]. Urinalysis ﬁndings were
frequently abnormal, with proteinuria and hae-
maturia being observed in more than half of the
patients. An elevated serum creatinine level
appears to be one of the best diagnostic signs, as
this is rather uncommon for most of the differen-
tial diagnoses (inﬂuenza-like illness, viral hepati-
tis, gastroenteritis or meningitis). In the present
study, hyperleukocytosis was less frequent
(18.7%) than reported previously [1,3,11,13,19].
The high frequency of lymphopenia (85.1%) is not
a classical ﬁnding and does not appear to have
been reported previously as a common feature of
leptospirosis. It remains to be determined whe-
ther this ﬁnding is speciﬁc to leptospirosis in the
Pontchaillou area, or whether previous series did
not address this issue speciﬁcally.
With the numerous different manifestations of
leptospirosis, clinicians must maintain a high
index of suspicion in order to make the correct
diagnosis. Moreover, initial serological testing is
often negative (53% in this study), which is
sometimes misinterpreted as an indication that a
patient does not have leptospirosis.
Although leptospirosis has been categorised
historically as an occupational illness of farmers,
ranch hands and military personnel, there has
been a temporal shift since the 1970s, with a
decreasing incidence of occupational exposure
and a concurrent increase in exposure linked to
recreational activities [1,3]. In the present study,
canoeing was the most frequent risk factor,
reported for nine patients with leptospirosis
during an 11-year period. However, the risk
linked to this activity remained low in the context
of the 1098 individuals registered as members of
canoeing clubs in the Pontchaillou area in 2001.
Infection with serovars belonging to the
Icterohaemorrhagiae serogroup has been reported
to be associated with an increased severity of
disease [3,14], and this was reﬂected in the
present study by the relatively high proportion
of patients infected presumptively with the ser-
ovar Copenhageni (belonging to the serogroup
Icterohaemorrhagiae) who were admitted to the
ICU. During an outbreak in Brazil with a high
(15%) case fatality rate, Leptospira serovar Copen-
hageni was isolated from 87% of the cases with
positive blood cultures [16]. The retrospective
design of the present study, the limited sample
size, and the spontaneous recovery of the few
patients who did not receive antibiotics, allowed
no conclusions regarding the beneﬁt of antibiotic
treatment for leptospirosis. However, this study,
conducted in a rural area of France, conﬁrmed
previous data regarding the protean clinical and
biologicalmanifestations of leptospirosis. The high
frequency of lymphopenia (85% of patients in this
series) has not been reported previously and could
be a useful diagnostic sign.
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